Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages

  Mårtensson, Linda ^a,c   Nilsson, Rune ^b   Ohlsson, Tomas ^a   Sjögren, Hans Olov ^a   Strand, Sven Erik ^a   Tennvall, Jan ^a  

^a LUND UNIVERSITY   (Sweden)

^b Mitra Medical AB   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID STREPTAVIDIN IN 111; AVIDIN; BIOTIN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR96; STREPTAVIDIN; UNCLASSIFIED DRUG;

ADSORPTION; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; BIOACCUMULATION; BIOTINYLATION; CONFERENCE PAPER; CONJUGATION; CONTROLLED STUDY; EXTRACORPOREAL AFFINITY ADSORPTION; ISOTOPE LABELING; LIVER; LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOSENSITIVITY; RAT; TISSUE DISTRIBUTION; TUMOR;

ADSORPTION; ANIMALS; BIOTIN; COLONIC NEOPLASMS; EXTRACORPOREAL CIRCULATION; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; LIVER; LYMPH NODES; ORGANOMETALLIC COMPOUNDS; PANCREAS; RATS; RATS, INBRED BN; STREPTAVIDIN; TISSUE DISTRIBUTION;

EID: 34848917109     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0891     Document Type: Conference Paper

References (30)

1. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792-8.
2. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med 2005;46:141-50S.
3. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
4. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5.
5. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348-57.
6. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802-7.
7. Strand S-E, Tennvall J, Sjögren H-O, et al. Extracorporeal techniques in radioimmunotherapy. In: Radioimmunotherapy of cancer. Abrams P, Fritzberg A, editors. NY: Marcel & Dekker, Inc.; 2000. p. 223-43.
8. Wilbur DS, Chyan MK, Hamlin DK, et al. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjugate Chem 2002;13:1079-92.
9. Garkavij M, Tennvall J, Strand SE, et al. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody. J Nucl Med 1997;38:895-901.
10. Lindén O, Kurkus J, Garkavij M, et al. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm 2005;20:457-66.
11. Hellström I, Garrgigues HJ, Garrgigues U, Hellström K-E. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le (y)-related cell surface antigens. Cancer Res 1990;50:2183-90.
12. Green NM. A Spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J 1965;94:23-4c.
13. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34.
14. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem 1997;8:595-604.
15. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003;44:437-45.
16. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000;15:15-29.
17. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6.
18. Zhang M, Yao Z, Saga T, et al. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody. J Nucl Med 1998;39:30-3.
19. Saga T, Weinstein JN, Jeong JM, et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res 1994;54:2160-5.
20. Maraveyas A, Rowlinson-Busza G, Murray S, Epenetos AA. Improving tumour targeting and decreasing normal tissue uptake byoptimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: studies in a nude mouse xenograft model. Int J Cancer 1998;78:610-7.
21. Sung C, van Osdol WW, Saga T, Neumann RD, Dedrick RL, Weinstein JN. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 1994;54:2166-75.
22. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med 1995;36:876-9.
23. Zhang M, Sakahara H, Yao Z, et al. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody. Nucl Med Biol 1997;24:61-4.
24. Yao Z, Zhang M, Sakahara H, et al. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment. Nucl Med Biol 1998;25:557-60.
25. Wilbur DS, Stayton PS, To R, et al. Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. Bioconjug Chem 1998;9:100-7.
26. Wilbur DS, Hamlin DK, Buhler KR, et al. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem 1998;9:322-30.
27. Wilbur DS, Hamlin DK, Meyer DL, et al. Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin. Bioconjug Chem 2002;13:611-20.
28. Breitz HB, Fisher DR, Goris ML, et al. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 1999;14:381-95.
29. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
30. Forero-Torres A, Shen S, Breitz H, et al. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 2005;20:379-90.